<br>        Inclusion Criteria:<br><br>          1. CP CML within 6 months of diagnosis<br><br>               -  CP-CML will be defined by (i) <15% blasts in bone marrow; (ii) <30% blasts plus<br>                  promyelocytes in bone marrow; (iii) <20% basophils in peripheral blood; (iv) =100<br>                  × 10^9/L platelets (=100,000/mm^3); (v) No evidence of extramedullary disease<br>                  except hepatosplenomegaly; AND (vi) No prior diagnosis of AP-CML or BP-CML<br><br>          2. Cytogenetic assessment must demonstrate the BCR-ABL fusion by presence of the t(9;22)<br>             Philadelphia chromosome<br><br>               -  (a)Variant translocations are only allowed provided they are assessable for<br>                  cytogenetic response utilizing conventional cytogenetic techniques; (b)<br>                  Conventional chromosome banding must be performed; AND (c) A minimum of 20<br>                  metaphases must be assessable at entry<br><br>          3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2<br><br>          4. Adequate hepatic function as defined by the following criteria:<br><br>             (a) Total serum bilirubin =1.5 x upper limit of normal (ULN), unless due to Gilbert's<br>             syndrome; (b) Alanine aminotransferase (ALT) =2.5 × ULN; AND (c) Aspartate<br>             aminotransferase (AST) =2.5 × ULN<br><br>          5. Adequate renal function as defined as defined by serum creatinine <1.5 x ULN<br><br>          6. Adequate pancreatic function as defined by serum lipase and amylase =1.5 × ULN<br><br>        Exclusion Criteria:<br><br>          1. Received prior imatinib therapy<br><br>          2. Received prior dasatinib therapy<br><br>          3. Received prior nilotinib therapy<br><br>          4. Received, for CML, any other systemic anticancer therapy, experimental therapy, or<br>             radiation therapy with the exception of anagrelide or hydroxyurea<br><br>          5. Major surgery within 28 days prior to initiating therapy<br><br>          6. History of bleeding disorder unrelated to CML<br><br>          7. History of acute pancreatitis within 1 year of study or history of chronic<br>             pancreatitis<br><br>          8. History of alcohol abuse<br><br>          9. Have uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)<br><br>         10. Clinically significant, uncontrolled, or active cardiovascular disease, specifically<br>             including, but not restricted to:<br><br>               1. Myocardial infarction, within 6 months prior to randomization<br><br>               2. Unstable angina within 6 months prior to randomization<br><br>               3. Congestive heart failure within 6 months prior to randomization<br><br>               4. History of clinically significant (as determined by the treating physician)<br>                  atrial arrhythmia or any ventricular arrhythmia<br><br>               5. Any history of ventricular arrhythmia<br><br>               6. Cerebrovascular accident or transient ischemic attack within 6 months prior to<br>                  randomization<br><br>               7. Any history of peripheral arterial occlusive disease requiring revascularization<br><br>               8. Any history of venous thromboembolism including deep venous thrombosis or<br>                  pulmonary embolism<br><br>         11. Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg).<br>             Patients with hypertension should be under treatment on study entry to effect blood<br>             pressure control<br><br>         12. Taking medications that are known to be associated with Torsades de Pointes<br><br>         13. Ongoing or active infection. The requirement for intravenous (IV) antibiotics is<br>             considered active infection<br><br>         14. Known history of human immunodeficiency virus (HIV). Testing is not required in the<br>             absence of history<br><br>         15. Pregnant or breastfeeding<br><br>         16. Malabsorption syndrome or other gastrointestinal illness that could affect oral<br>             absorption of study drugs<br><br>         17. Diagnosed with or received anticancer therapy for another primary malignancy within 3<br>             years prior to entry (except for non-melanoma skin cancer or cervical cancer in situ)<br><br>         18. Any condition or illness that, in the opinion of the Investigator, would compromise<br>             patient safety or interfere with the evaluation of the drug<br>      ;<br>        Inclusion Criteria:<br><br>          1. CP CML within 6 months of diagnosis<br><br>               -  CP-CML will be defined by (i) <15% blasts in bone marrow; (ii) <30% blasts plus<br>                  promyelocytes in bone marrow; (iii) <20% basophils in peripheral blood; (iv) =100<br>                  × 10^9/L platelets (=100,000/mm^3); (v) No evidence of extramedullary disease<br>                  except hepatosplenomegaly; AND (vi) No prior diagnosis of AP-CML or BP-CML<br><br>          2. Cytogenetic assessment must demonstrate the BCR-ABL fusion by presence of the t(9;22)<br>             Philadelphia chromosome<br><br>               -  (a)Variant translocations are only allowed provided they are assessable for<br>                  cytogenetic response utilizing conventional cytogenetic techniques; (b)<br>                  Conventional chromosome banding must be performed; AND (c) A minimum of 20<br>                  metaphases must be assessable at entry<br><br>          3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2<br><br>          4. Adequate hepatic function as defined by the following criteria:<br><br>             (a) Total serum bilirubin =1.5 x upper limit of normal (ULN), unless due to Gilbert's<br>             syndrome; (b) Alanine aminotransferase (ALT) =2.5 × ULN; AND (c) Aspartate<br>             aminotransferase (AST) =2.5 × ULN<br><br>          5. Adequate renal function as defined as defined by serum creatinine <1.5 x ULN<br><br>          6. Adequate pancreatic function as defined by serum lipase and amylase =1.5 × ULN<br><br>        Exclusion Criteria:<br><br>          1. Received prior imatinib therapy<br><br>          2. Received prior dasatinib therapy<br><br>          3. Received prior nilotinib therapy<br><br>          4. Received, for CML, any other systemic anticancer therapy, experimental therapy, or<br>             radiation therapy with the exception of anagrelide or hydroxyurea<br><br>          5. Major surgery within 28 days prior to initiating therapy<br><br>          6. History of bleeding disorder unrelated to CML<br><br>          7. History of acute pancreatitis within 1 year of study or history of chronic<br>             pancreatitis<br><br>          8. History of alcohol abuse<br><br>          9. Have uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)<br><br>         10. Clinically significant, uncontrolled, or active cardiovascular disease, specifically<br>             including, but not restricted to:<br><br>               1. Myocardial infarction, within 6 months prior to randomization<br><br>               2. Unstable angina within 6 months prior to randomization<br><br>               3. Congestive heart failure within 6 months prior to randomization<br><br>               4. History of clinically significant (as determined by the treating physician)<br>                  atrial arrhythmia or any ventricular arrhythmia<br><br>               5. Any history of ventricular arrhythmia<br><br>               6. Cerebrovascular accident or transient ischemic attack within 6 months prior to<br>                  randomization<br><br>               7. Any history of peripheral arterial occlusive disease requiring revascularization<br><br>               8. Any history of venous thromboembolism including deep venous thrombosis or<br>                  pulmonary embolism<br><br>         11. Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg).<br>             Patients with hypertension should be under treatment on study entry to effect blood<br>             pressure control<br><br>         12. Taking medications that are known to be associated with Torsades de Pointes<br><br>         13. Ongoing or active infection. The requirement for intravenous (IV) antibiotics is<br>             considered active infection<br><br>         14. Known history of human immunodeficiency virus (HIV). Testing is not required in the<br>             absence of history<br><br>         15. Pregnant or breastfeeding<br><br>         16. Malabsorption syndrome or other gastrointestinal illness that could affect oral<br>             absorption of study drugs<br><br>         17. Diagnosed with or received anticancer therapy for another primary malignancy within 3<br>             years prior to entry (except for non-melanoma skin cancer or cervical cancer in situ)<br><br>         18. Any condition or illness that, in the opinion of the Investigator, would compromise<br>             patient safety or interfere with the evaluation of the drug<br>      ;<br>        Inclusion Criteria:<br><br>          1. CP CML within 6 months of diagnosis<br><br>               -  CP-CML will be defined by (i) <15% blasts in bone marrow; (ii) <30% blasts plus<br>                  promyelocytes in bone marrow; (iii) <20% basophils in peripheral blood; (iv) =100<br>                  × 10^9/L platelets (=100,000/mm^3); (v) No evidence of extramedullary disease<br>                  except hepatosplenomegaly; AND (vi) No prior diagnosis of AP-CML or BP-CML<br><br>          2. Cytogenetic assessment must demonstrate the BCR-ABL fusion by presence of the t(9;22)<br>             Philadelphia chromosome<br><br>               -  (a)Variant translocations are only allowed provided they are assessable for<br>                  cytogenetic response utilizing conventional cytogenetic techniques; (b)<br>                  Conventional chromosome banding must be performed; AND (c) A minimum of 20<br>                  metaphases must be assessable at entry<br><br>          3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2<br><br>          4. Adequate hepatic function as defined by the following criteria:<br><br>             (a) Total serum bilirubin =1.5 x upper limit of normal (ULN), unless due to Gilbert's<br>             syndrome; (b) Alanine aminotransferase (ALT) =2.5 × ULN; AND (c) Aspartate<br>             aminotransferase (AST) =2.5 × ULN<br><br>          5. Adequate renal function as defined as defined by serum creatinine <1.5 x ULN<br><br>          6. Adequate pancreatic function as defined by serum lipase and amylase =1.5 × ULN<br><br>        Exclusion Criteria:<br><br>          1. Received prior imatinib therapy<br><br>          2. Received prior dasatinib therapy<br><br>          3. Received prior nilotinib therapy<br><br>          4. Received, for CML, any other systemic anticancer therapy, experimental therapy, or<br>             radiation therapy with the exception of anagrelide or hydroxyurea<br><br>          5. Major surgery within 28 days prior to initiating therapy<br><br>          6. History of bleeding disorder unrelated to CML<br><br>          7. History of acute pancreatitis within 1 year of study or history of chronic<br>             pancreatitis<br><br>          8. History of alcohol abuse<br><br>          9. Have uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)<br><br>         10. Clinically significant, uncontrolled, or active cardiovascular disease, specifically<br>             including, but not restricted to:<br><br>               1. Myocardial infarction, within 6 months prior to randomization<br><br>               2. Unstable angina within 6 months prior to randomization<br><br>               3. Congestive heart failure within 6 months prior to randomization<br><br>               4. History of clinically significant (as determined by the treating physician)<br>                  atrial arrhythmia or any ventricular arrhythmia<br><br>               5. Any history of ventricular arrhythmia<br><br>               6. Cerebrovascular accident or transient ischemic attack within 6 months prior to<br>                  randomization<br><br>               7. Any history of peripheral arterial occlusive disease requiring revascularization<br><br>               8. Any history of venous thromboembolism including deep venous thrombosis or<br>                  pulmonary embolism<br><br>         11. Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg).<br>             Patients with hypertension should be under treatment on study entry to effect blood<br>             pressure control<br><br>         12. Taking medications that are known to be associated with Torsades de Pointes<br><br>         13. Ongoing or active infection. The requirement for intravenous (IV) antibiotics is<br>             considered active infection<br><br>         14. Known history of human immunodeficiency virus (HIV). Testing is not required in the<br>             absence of history<br><br>         15. Pregnant or breastfeeding<br><br>         16. Malabsorption syndrome or other gastrointestinal illness that could affect oral<br>             absorption of study drugs<br><br>         17. Diagnosed with or received anticancer therapy for another primary malignancy within 3<br>             years prior to entry (except for non-melanoma skin cancer or cervical cancer in situ)<br><br>         18. Any condition or illness that, in the opinion of the Investigator, would compromise<br>             patient safety or interfere with the evaluation of the drug<br>      ;<br>        Inclusion Criteria:<br><br>          1. CP CML within 6 months of diagnosis<br><br>               -  CP-CML will be defined by (i) <15% blasts in bone marrow; (ii) <30% blasts plus<br>                  promyelocytes in bone marrow; (iii) <20% basophils in peripheral blood; (iv) =100<br>                  × 10^9/L platelets (=100,000/mm^3); (v) No evidence of extramedullary disease<br>                  except hepatosplenomegaly; AND (vi) No prior diagnosis of AP-CML or BP-CML<br><br>          2. Cytogenetic assessment must demonstrate the BCR-ABL fusion by presence of the t(9;22)<br>             Philadelphia chromosome<br><br>               -  (a)Variant translocations are only allowed provided they are assessable for<br>                  cytogenetic response utilizing conventional cytogenetic techniques; (b)<br>                  Conventional chromosome banding must be performed; AND (c) A minimum of 20<br>                  metaphases must be assessable at entry<br><br>          3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2<br><br>          4. Adequate hepatic function as defined by the following criteria:<br><br>             (a) Total serum bilirubin =1.5 x upper limit of normal (ULN), unless due to Gilbert's<br>             syndrome; (b) Alanine aminotransferase (ALT) =2.5 × ULN; AND (c) Aspartate<br>             aminotransferase (AST) =2.5 × ULN<br><br>          5. Adequate renal function as defined as defined by serum creatinine <1.5 x ULN<br><br>          6. Adequate pancreatic function as defined by serum lipase and amylase =1.5 × ULN<br><br>        Exclusion Criteria:<br><br>          1. Received prior imatinib therapy<br><br>          2. Received prior dasatinib therapy<br><br>          3. Received prior nilotinib therapy<br><br>          4. Received, for CML, any other systemic anticancer therapy, experimental therapy, or<br>             radiation therapy with the exception of anagrelide or hydroxyurea<br><br>          5. Major surgery within 28 days prior to initiating therapy<br><br>          6. History of bleeding disorder unrelated to CML<br><br>          7. History of acute pancreatitis within 1 year of study or history of chronic<br>             pancreatitis<br><br>          8. History of alcohol abuse<br><br>          9. Have uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)<br><br>         10. Clinically significant, uncontrolled, or active cardiovascular disease, specifically<br>             including, but not restricted to:<br><br>               1. Myocardial infarction, within 6 months prior to randomization<br><br>               2. Unstable angina within 6 months prior to randomization<br><br>               3. Congestive heart failure within 6 months prior to randomization<br><br>               4. History of clinically significant (as determined by the treating physician)<br>                  atrial arrhythmia or any ventricular arrhythmia<br><br>               5. Any history of ventricular arrhythmia<br><br>               6. Cerebrovascular accident or transient ischemic attack within 6 months prior to<br>                  randomization<br><br>               7. Any history of peripheral arterial occlusive disease requiring revascularization<br><br>               8. Any history of venous thromboembolism including deep venous thrombosis or<br>                  pulmonary embolism<br><br>         11. Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg).<br>             Patients with hypertension should be under treatment on study entry to effect blood<br>             pressure control<br><br>         12. Taking medications that are known to be associated with Torsades de Pointes<br><br>         13. Ongoing or active infection. The requirement for intravenous (IV) antibiotics is<br>             considered active infection<br><br>         14. Known history of human immunodeficiency virus (HIV). Testing is not required in the<br>             absence of history<br><br>         15. Pregnant or breastfeeding<br><br>         16. Malabsorption syndrome or other gastrointestinal illness that could affect oral<br>             absorption of study drugs<br><br>         17. Diagnosed with or received anticancer therapy for another primary malignancy within 3<br>             years prior to entry (except for non-melanoma skin cancer or cervical cancer in situ)<br><br>         18. Any condition or illness that, in the opinion of the Investigator, would compromise<br>             patient safety or interfere with the evaluation of the drug<br>